Elite Pharmaceuticals acquires three ANDAs from Nostrum Laboratories for $900k

ELITE PHARMACEUTICALS INC /NV/

Acquired ANDAs for generic Norco (hydrocodone/APAP), Percocet (oxycodone/APAP), and Dolophine (methadone) from Nostrum.
Paid $900,000 cash; also received royalty-free perpetual license for manufacturing technology.
Asset Purchase Agreement signed June 17, 2024; transaction closed June 21, 2024.

item 1.01

ELITE PHARMACEUTICALS INC /NV/ filing history →

Source: SEC EDGAR

accession 0001493152-24-024720

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.